Patents Assigned to Crusade Laboratories Limited
-
Patent number: 8067012Abstract: Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the ?34.5 gene in the long repeat region (RL) such that the ?34.5 gene is a non-functional, manufacture of medicaments and methods of testing cancer in mammals employing HSV mutant.Type: GrantFiled: January 22, 2010Date of Patent: November 29, 2011Assignees: Crusade Laboratories Limited, The Wistar InstituteInventors: Alasdair Roderick MacLean, Susanne Moira Brown, Nigel William Fraser, Bruce Paul Randazzo
-
Publication number: 20110244576Abstract: There is provided an HSV complex which comprises an avirulent HSV and a targeting agent which allows the HSV particle to infect and lyse a specific targeted cell. The inventors have found a way in which avirulent HSV can be targeted to disease cells, e.g. cancer cells, by incorporating an antibody binding domain into one or more viral glycoproteins.Type: ApplicationFiled: April 13, 2011Publication date: October 6, 2011Applicant: CRUSADE LABORATORIES LIMITEDInventors: Susanne Moira Brown, Joe Conner
-
Publication number: 20110195053Abstract: A mutant herpes simplex virus which has been modified in the ?34.5 gene such that the gene is non-functional is used to treat a non-neuronal cancer such as a mesothelioma, ovarian carcinoma, bladder cancer or melanoma. Typically, the mutant herpes simplex virus has been modified within the BamHI restriction fragment of the long terminal repeat of the viral genome.Type: ApplicationFiled: April 20, 2011Publication date: August 11, 2011Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, CRUSADE LABORATORIES LIMITED, WISTAR INSTITUTEInventors: Susanne M. Brown, Alasdair R. Maclean, Nigel W. Fraser, Bruce P. Randazzo, Steven Albelda, Larry Kaiser, John Kucharczuk
-
Publication number: 20110158948Abstract: Herpes Simplex Viruses are disclosed having single-chain antibodies (scFv) embedded in the viral envelope via fusion with glycoprotein D and with glycoprotein H and L.Type: ApplicationFiled: January 12, 2011Publication date: June 30, 2011Applicant: CRUSADE LABORATORIES LIMITEDInventors: Susanne Moira Brown, Guy Michael Gary Hamilton
-
Patent number: 7943144Abstract: There is provided an HSV Complex which comprises an avirulent HSV and a targeting agent which allows the HSV particle to infect and lyse a specific targeted cell. The inventors have found a way in which avirulent HSV can be targeted to disease cells, e.g. cancer cells, by incorporating an antibody binding domain into one or more viral glycoproteins.Type: GrantFiled: February 12, 2003Date of Patent: May 17, 2011Assignee: Crusade Laboratories LimitedInventors: Susanne Moira Brown, Joe Conner
-
Patent number: 7897146Abstract: The use of Herpes Simplex Virus (HSV) in the treatment of tumour by extratumoural administration of HSV, and the use of HSV in treatment of tumour by combination therapy with a pharmaceutical wherein the HSV and/or pharmaceutical is administered at an extratumoural location, is disclosed.Type: GrantFiled: August 30, 2006Date of Patent: March 1, 2011Assignee: Crusade Laboratories LimitedInventors: Susanne Moira Brown, Guy Michael Gary Hamilton
-
Publication number: 20100272691Abstract: Herpes Simplex Viruses are disclosed having single-chain antibodies (scFv) embedded in the viral envelope via fusion with glycoprotein D and with glycoprotein H and L.Type: ApplicationFiled: April 2, 2008Publication date: October 28, 2010Applicant: CRUSADE LABORATORIES LIMITEDInventor: Joe Conner
-
Publication number: 20100172872Abstract: Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the ?34.5 gene in the long repeat region (RL) such that the ?34.5 gene is a non-functional, manufacture of medicaments and methods of testing cancer in mammals employing HSV mutant.Type: ApplicationFiled: January 22, 2010Publication date: July 8, 2010Applicants: CRUSADE LABORATORIES LIMITED, THE WISTAR INSTITUTEInventors: Alasdair Roderick MacLean, Susanne Moira Brown, Nigel William Fraser, Bruce Paul Randazzo
-
Publication number: 20100092515Abstract: A herpes simplex virus is disclosed in which the herpes simplex virus genome comprises a nucleic acid sequence encoding an ING4 polypeptide.Type: ApplicationFiled: February 15, 2008Publication date: April 15, 2010Applicant: CRUSADE LABORATORIES LIMITEDInventors: Joe Conner, Susanne Moira Brown
-
Patent number: 7674468Abstract: Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the ?34.5 gene in the long repeat region (RL) such that the ?34.5 gene is a non-functional, manufacture of medicaments and methods of testing cancer in mammals employing HSV mutant.Type: GrantFiled: June 13, 2005Date of Patent: March 9, 2010Assignees: Crusade Laboratories Limited, The Wistar InstituteInventors: Alasdair Roderick MacLean, Susanne Moira Brown, Nigel William Fraser, Bruce Paul Randazzo
-
Publication number: 20090274728Abstract: An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of repressing or silencing expression of squamous cell carcinoma related oncogene (SCCRO) nucleic acid or polypeptide are disclosed together with methods for generation and applications of such viruses.Type: ApplicationFiled: May 6, 2009Publication date: November 5, 2009Applicants: CRUSADE LABORATORIES LIMITED, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Susanne Moira Brown, Bhuvanesh Singh, Ian Ganly, Paul Dunn
-
Publication number: 20090208460Abstract: An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a nitroreductase (NTR) is disclosed. Disclosed herpes simplex viruses are indicated to be useful in the treatment of cancer which may involve gene directed enzyme prodrug therapy.Type: ApplicationFiled: January 21, 2009Publication date: August 20, 2009Applicant: CRUSADE LABORATORIES LIMITEDInventors: Susanne Moira Brown, Paul Dunn
-
Publication number: 20090176203Abstract: A method of generating a mutant Herpes Simplex Virus (HSV) is disclosed, wherein the generated HSV genome comprises nucleic acid encoding a nucleic acid sequence of interest, the method comprising the steps of: i. providing a nucleic acid vector comprising nucleic acid encoding first and second site specific recombination sequences and a nucleic acid encoding a nucleic acid sequence of interest between said site specific recombination sequences; ii. providing an HSV, the genome of which comprises third and fourth site specific recombination sequences; iii. contacting said nucleic acid vector of (i) with said HSV of (ii) together with one or more recombinase enzymes capable of catalysing site specific recombination between the site specific recombination sequences of said nucleic acid vector and said HSV; iv. identifying HSV containing the nucleic acid sequence of interest, wherein steps i-iii are conducted in a cell-free system.Type: ApplicationFiled: May 4, 2007Publication date: July 9, 2009Applicant: CRUSADE LABORATORIES LIMITEDInventor: Joe Conner
-
Patent number: 7498161Abstract: An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a nitroreductase (NTR) is disclosed. Disclosed herpes simplex viruses are indicated to be useful in the treatment of cancer which may involve gene directed enzyme prodrug therapy.Type: GrantFiled: November 17, 2004Date of Patent: March 3, 2009Assignee: Crusade Laboratories LimitedInventors: Susanne Moira Brown, Paul Dunn
-
Publication number: 20090010889Abstract: The use of Herpes Simplex Virus (HSV) in the treatment of tumour by extratumoural administration of said HSV, and the use of HSV in treatment of tumour by combination therapy with a pharmaceutical wherein the HSV and/or pharmaceutical is administered at an extratumoural location, is disclosed.Type: ApplicationFiled: August 30, 2006Publication date: January 8, 2009Applicant: CRUSADE LABORATORIES LIMITEDInventors: Susanne Moira Brown, Guy Michael Gary Hamilton